Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 11

Future Perspectives on ADCs in Breast Cancer

,

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

EP. 1: Overview of Current ADCs in Breast Cancer
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
EP. 5: Navigating SG-related Diarrhea
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
Now Viewing
EP. 11: Future Perspectives on ADCs in Breast Cancer
EP. 12: Expert Insights: Investigational ADCs Safety Profiles
EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

  • Please review some ongoing clinical trials and studies utilizing investigational ADCs in breast cancer that are in progress that may be interesting. (See below for a few suggestions. Please include others if not included.)
  • 1.Bartsch R. et al. Patritumab deruxtecan (HER3-DXd) in Active Brain Mets. TUXEDO-3 Phase II trial. ASCO 2024 Abstract
  • 2.Bardia A et al, Final Results TROPION-Breast01. ESMO 2023 Abstract.